CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 25 of 27 entries

View as:

Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia

Phase: N/A Priority: Normal

NCT ID: NCT00017589 Org: User:

Start: 12/31/00 End: 05/31/06 Due: 05/31/07

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

Phase: N/A Priority: Normal

NCT ID: NCT00518895 Org: User:

Start: 07/31/07 End: 05/31/11 Due: 05/31/12

Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal

NCT ID: NCT00017602 Org: User:

Start: 12/31/00 End: 04/30/09 Due: 04/30/10

Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal

NCT ID: NCT00078234 Org: User:

Start: 11/30/03 End: 09/30/10 Due: 09/30/11

A Phase I Study of G3139 Subcutaneous in Solid Tumors

Phase: N/A Priority: Normal

NCT ID: NCT00543231 Org: User:

Start: 12/31/05 End: 12/31/06 Due: 12/31/07

Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer

Phase: N/A Priority: Normal

NCT ID: NCT01095120 Org: User:

Start: 03/31/10 End: 10/31/12 Due: 10/31/13

Abraxane and Temodar Plus Genasense in Advanced Melanoma

Phase: N/A Priority: Normal

NCT ID: NCT00409383 Org: User:

Start: 11/30/06 End: 06/30/13 Due: 06/30/14

This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)

Phase: N/A Priority: Normal

NCT ID: NCT00517218 Org: User:

Start: 06/30/06 End: 06/30/09 Due: 06/30/10

Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH

Phase: N/A Priority: Normal

NCT ID: NCT01092585 Org: User:

Start: 02/28/10 End: 03/31/12 Due: 03/31/13

Tesetaxel for Previously Treated Patients With Bladder Cancer

Phase: N/A Priority: Normal

NCT ID: NCT01215877 Org: User:

Start: 09/30/10 End: 12/31/12 Due: 12/31/13

Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules

Phase: N/A Priority: Normal

NCT ID: NCT01170975 Org: User:

Start: 06/30/10 End: 04/30/11 Due: 04/30/12

Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer

Phase: N/A Priority: Normal

NCT ID: NCT01573468 Org: User:

Start: 04/30/12 End: 08/31/14 Due: 08/31/15

Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00030641 Org: User:

Start: 10/31/01 End: - Due: -

Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal

NCT ID: NCT00024440 Org: User:

Start: 07/31/01 End: 02/28/07 Due: 02/28/08

Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer

Phase: N/A Priority: Normal

NCT ID: NCT01609127 Org: User:

Start: 05/31/12 End: 07/31/14 Due: 07/31/15

Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment

Phase: N/A Priority: Normal

NCT ID: NCT00543205 Org: User:

Start: 08/31/05 End: 05/31/07 Due: 05/31/08

Study of Tesetaxel in Japanese Patients With Solid Tumors

Phase: N/A Priority: Normal

NCT ID: NCT01337310 Org: User:

Start: 04/30/11 End: 09/30/12 Due: 09/30/13

Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors

Phase: N/A Priority: Normal

NCT ID: NCT00636545 Org: User:

Start: 05/31/07 End: 03/31/10 Due: 03/31/11

Tesetaxel as First-line Therapy for Metastatic Breast Cancer

Phase: N/A Priority: Normal

NCT ID: NCT01221870 Org: User:

Start: 11/30/10 End: 01/31/13 Due: 01/31/14

Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer

Phase: N/A Priority: Normal

NCT ID: NCT01348009 Org: User:

Start: 05/31/11 End: 01/31/14 Due: 01/31/15

A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors

Phase: N/A Priority: Normal

NCT ID: NCT01315431 Org: User:

Start: 03/31/11 End: 10/31/12 Due: 10/31/13

A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine

Phase: N/A Priority: Normal

NCT ID: NCT00542893 Org: User:

Start: 04/30/06 End: 09/30/07 Due: 09/30/08

Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma

Phase: N/A Priority: Normal

NCT ID: NCT00016263 Org: User:

Start: 07/31/00 End: 12/31/04 Due: 12/31/05

Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal

NCT ID: NCT00021749 Org: User:

Start: 01/31/01 End: - Due: -

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Phase: N/A Priority: Normal

NCT ID: NCT01296243 Org: User:

Start: 02/28/11 End: 02/28/15 Due: 02/28/16

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia	NCT00017589	Genta Incorporated	user2@example.com	None	2000-12-31	2006-05-31	2007-05-31	-	-	2025-07-14
Trial of Dacarbazine With or Without Genasense in Advanced Melanoma	NCT00518895	Genta Incorporated	user2@example.com	None	2007-07-31	2011-05-31	2012-05-31	-	-	2025-07-14
Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma	NCT00017602	Genta Incorporated	user2@example.com	None	2000-12-31	2009-04-30	2010-04-30	-	-	2025-07-14
Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia	NCT00078234	Genta Incorporated	user2@example.com	None	2003-11-30	2010-09-30	2011-09-30	-	-	2025-07-14
A Phase I Study of G3139 Subcutaneous in Solid Tumors	NCT00543231	Genta Incorporated	user2@example.com	None	2005-12-31	2006-12-31	2007-12-31	-	-	2025-07-14
Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer	NCT01095120	Genta Incorporated	user2@example.com	None	2010-03-31	2012-10-31	2013-10-31	-	-	2025-07-14
Abraxane and Temodar Plus Genasense in Advanced Melanoma	NCT00409383	Genta Incorporated	user2@example.com	None	2006-11-30	2013-06-30	2014-06-30	-	-	2025-07-14
This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)	NCT00517218	Genta Incorporated	user2@example.com	None	2006-06-30	2009-06-30	2010-06-30	-	-	2025-07-14
Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH	NCT01092585	Genta Incorporated	user2@example.com	None	2010-02-28	2012-03-31	2013-03-31	-	-	2025-07-14
Tesetaxel for Previously Treated Patients With Bladder Cancer	NCT01215877	Genta Incorporated	user2@example.com	None	2010-09-30	2012-12-31	2013-12-31	-	-	2025-07-14
Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules	NCT01170975	Genta Incorporated	user2@example.com	None	2010-06-30	2011-04-30	2012-04-30	-	-	2025-07-14
Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer	NCT01573468	Genta Incorporated	user2@example.com	None	2012-04-30	2014-08-31	2015-08-31	-	-	2025-07-14
Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer	NCT00030641	Genta Incorporated	user2@example.com	None	2001-10-31	-	-	-	-	2025-07-14
Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia	NCT00024440	Genta Incorporated	user2@example.com	None	2001-07-31	2007-02-28	2008-02-28	-	-	2025-07-14
Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer	NCT01609127	Genta Incorporated	user2@example.com	None	2012-05-31	2014-07-31	2015-07-31	-	-	2025-07-14
Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment	NCT00543205	Genta Incorporated	user2@example.com	None	2005-08-31	2007-05-31	2008-05-31	-	-	2025-07-14
Study of Tesetaxel in Japanese Patients With Solid Tumors	NCT01337310	Genta Incorporated	user2@example.com	None	2011-04-30	2012-09-30	2013-09-30	-	-	2025-07-14
Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors	NCT00636545	Genta Incorporated	user2@example.com	None	2007-05-31	2010-03-31	2011-03-31	-	-	2025-07-14
Tesetaxel as First-line Therapy for Metastatic Breast Cancer	NCT01221870	Genta Incorporated	user2@example.com	None	2010-11-30	2013-01-31	2014-01-31	-	-	2025-07-14
Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer	NCT01348009	Genta Incorporated	user2@example.com	None	2011-05-31	2014-01-31	2015-01-31	-	-	2025-07-14
A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors	NCT01315431	Genta Incorporated	user2@example.com	None	2011-03-31	2012-10-31	2013-10-31	-	-	2025-07-14
A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine	NCT00542893	Genta Incorporated	user2@example.com	None	2006-04-30	2007-09-30	2008-09-30	-	-	2025-07-14
Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma	NCT00016263	Genta Incorporated	user2@example.com	None	2000-07-31	2004-12-31	2005-12-31	-	-	2025-07-14
Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia	NCT00021749	Genta Incorporated	user2@example.com	None	2001-01-31	-	-	-	-	2025-07-14
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer	NCT01296243	Genta Incorporated	user2@example.com	None	2011-02-28	2015-02-28	2016-02-28	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance